CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis.

PJ Perrin, JH Maldonado, TA Davis… - … (Baltimore, Md.: 1950 …, 1996 - journals.aai.org
PJ Perrin, JH Maldonado, TA Davis, CH June, MK Racke
Journal of immunology (Baltimore, Md.: 1950), 1996journals.aai.org
The B7 family of cell surface molecules expressed on APC provides accessory signals to T
cells via either CD28 or CTLA-4. However, while CD28 transduces a costimulatory signal
that is required for an optimal immune response, CTLA-4 transmits a negative signal. These
studies use an anti-CTLA-4 mAb to directly address the role of this T cell surface molecule in
experimental allergic encephalomyelitis (EAE). CTLA-4 regulation of disease was assessed
during initial immune cell interactions and during the effector stage of the encephalitogenic …
Abstract
The B7 family of cell surface molecules expressed on APC provides accessory signals to T cells via either CD28 or CTLA-4. However, while CD28 transduces a costimulatory signal that is required for an optimal immune response, CTLA-4 transmits a negative signal. These studies use an anti-CTLA-4 mAb to directly address the role of this T cell surface molecule in experimental allergic encephalomyelitis (EAE). CTLA-4 regulation of disease was assessed during initial immune cell interactions and during the effector stage of the encephalitogenic immune response. The effects of anti-CTLA-4 treatment were schedule dependent. CTLA-4 blockade during the onset of clinical symptoms markedly exacerbated disease, enhancing mortality. Disease exacerbation was associated with enhanced production of the encephalitogenic cytokines TNF-alpha, IFN-gamma and IL-2. Hence, CTLA-4 regulates the intensity of the autoimmune response in EAE, attenuating inflammatory cytokine production and clinical disease manifestations.
journals.aai.org